The AUA Expert Exchange Podcast: Discussions About Managing GU Cancer (2020)
To encourage consistent, high quality, evidence-based treatment of patients, the AUA has created a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. The activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Based on the documented need for additional education in prostate cancer, bladder cancer, and renal cell carcinoma, the AUA has identified expert faculty to engage in a series of ten interactive interview-style episodes. The AUA Expert Exchange Podcast: Discussions About Managing GU Cancer is designed to address very specific learning opportunities and reach the urologist in an easy, flexible way with smaller, targeted updates.
The 10 topic-specific podcasts will focus on the following:
- Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Part 1
- Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Part 2
- Genetic Testing and Personalized Medicine in Prostate Cancer
- Addressing Disparities in Prostate Cancer Care
- The Expanding Role of Immune Checkpoint Inhibitors in MIBC and NMIBC
- Sequencing of Agents and Combination of Treatment Options for Bladder Cancer
- Chemo-ablation of Upper-Tract Urothelial Carcinoma
RENAL CELL CARCINOMA
- Immune Checkpoint Inhibitors in RCC
- Targeted Therapies and Integration with Surgical Management of RCC
- Sequencing of Agents and Combination of Treatment for Metastatic RCC
This educational series is supported by independent educational grants from:
Bristol Myers Squibb
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
UroGen Pharma, Inc.
At the conclusion of these activities, participants will be able to:
ADVANCED PROSTATE CANCER: AUA/ASTRO/SUO GUIDELINE PART 1
- Analyze breakthrough treatments in the management of advanced and metastatic hormone sensitive prostate cancer (mHSPC) and castration resistant prostate cancer (CRPC).
- Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.
- Describe the indications, sequencing and combinations for treatment with approved agents in the management of mHSPC and nmCRPC.
ADVANCED PROSTATE CANCER: AUA/ASTRO/SUO GUIDELINE PART 2
- Review the evidence and outcomes on the treatment of M1 HSPC, MO CRPC and M1 CRPC as outlined in the newly updated AUA Advanced, Metastatic and CRPC guidelines.
- Improve diagnostic and therapeutic decision-making processes by illustrating the application of these guidelines in urological practice.
GENETIC TESTING AND PERSONALIZED MEDICINE IN PROSTATE CANCER
- Identify the role of genetic testing in men with advanced, metastatic and CRPC.
- State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.
- Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results.
- Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors.
ADDRESSING DISPARITIES IN PROSTATE CANCER CARE
- Examine racial and geographic disparities in in prostate cancer and prostate cancer care.
- Identify important causes for disparities as well as possible remedies to address these causes.
THE EXPANDING ROLE OF IMMUNE CHECKPOINT INHIBITORS IN MIBC AND NMIBC
- Recognize both historic and newer immunotherapy options in the treatment of bladder cancer.
- Describe the mechanism of action of immunotherapy regimens.
- Identify and manage the adverse events related to these agents.
SEQUENCING OF AGENTS AND COMBINATION OF TREATMENT OPTIONS FOR BLADDER CANCER
- Evaluate treatment plans including the sequencing and combination of treatment options for individual patients.
- Explain best practices in MIBC and NMIBC patient selection for various treatment options.
- Facilitate discussions with patients and caregivers regarding their treatment options.
CHEMO-ABLATION OF UPPER-TRACT UROTHELIAL CARCINOMA
- Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment.
- Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options.
IMMUNE CHECKPOINT INHIBITORS IN RCC
- Discuss the current immunotherapy options available for the treatment of RCC.
- Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC.
- Identify and manage immune related adverse events.
TARGETED THERAPIES AND INTEGRATION WITH SURGICAL MANAGEMENT OF RCC
- Describe new and emerging targeted for patients with locally-advanced and advanced kidney cancer and the role of adjuvant therapy.
- Review the mechanisms of action, efficacy, and safety of currently available targeted treatment of RCC.
- Describe the key elements on how to integrate surgery (timing and rationale) with systemic targeted therapy in managing a patient with advanced kidney cancer.
- Facilitate discussions with patients and caregivers regarding RCC treatment options.
SEQUENCING AND COMBINATION OF TREATMENT FOR METASTATIC RCC
- Explain the sequencing of novel therapies and be able to identify patient progression of disease.
- Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer.
Education Council & COI Reviewer Disclosures
Education Council & COI Reviewer Disclosures.pdf
AUA Office of Education Staff has nothing to disclose.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Estimated time to complete this activity: 5.0 hours
Release Date: October, 2020
Expiration Date: December, 2021
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 5.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.